This edition of FT TOE covers technological developments and commercial implications of various neuromodulation therapies that are redefining the standard of care offered by traditional drug-based therapies. The issue covers a snapshot of the global neuromodulation industry, highlighting the intensity of research and commercial prospects for newer clinical applications of these therapies. Detailed analysis of the market and technological drivers and challenges are covered, along with their influence on value of care offered to patients. The issue covers four innovation portfolios within this technology sector, including information and analyst insights on potential business models that could redefine healthcare.
The Future Tech TechVision Opportunity Engine (TOE) captures emerging innovations in research and development, or profile existing technologies which have seen a resurgence in terms of new markets and applications. It usually provides a technology overview, drivers, challenges, research and development, analyst insights and key patent information. In some cases, technology convergence scenarios and future growth opportunities are outlined. It covers innovations and technologies in a variety of industry spaces including manufacturing, sensors, electronics, information and communications technologies, networks, lighting technologies, healthcare, medical devices, materials and coatings, and developments in the energy sector that contribute toward a sustainable and greener world.
Key Topics Covered:
1. Industry Snapshot of Neuromodulation Therapies
Most Prescribed Neuromodulation Therapies Target Low Back Pain
The Clinical Utilization of Neuromodulators is Extending the Way Patients Undertake Therapies
OEM Efforts to Expand Marketing Channels Are Focused on Widening Clinical Applications
Demand for Precise Innervation Triggers Initiatives for Improved Design of Stimulation Leads
Entry of New Participants with Innovative Technologies Affects Pipeline of OEMs
2. Key Technology Developments in Neuromodulation Therapies
Coin-sized Bioelectronic Device for Chronic Conditions
Implantable Neuromodulation Therapy for Inflammatory Diseases
Implantable Neuromodulator for Heart Failure and Hypertension
Cardiac Contractility Modulation for Chronic Heart Failure
3. IP Landscape of Neuromodulation Therapies
The United States has Top Rated Jurisdiction for Patents on Neuromodulation Therapies
Optogenetic Therapies for Movement Disorders
Implantable Medical Device having a Conducive Coating
4. Analyst Insights
Demand for Non-invasive and Collaborative Care Drive Technology-enabled Business Models
OEMs Need to Transfer Cost Savings across the Value Chain when Evaluating Global Growth Strategies
5. Key Contacts
For more information about this report visit http://www.researchandmarkets.com/research/rz4ht4/developments_in.